Hirata K, Horikoshi N, Aiba K, Okazaki M, Denno R, Sasaki K, et al. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res. 1999;5:2000–5.

CAS  PubMed  Google Scholar 

Shirasaka T. Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas. Jpn J Clin Oncol. 2009;39:2–15.

Article  PubMed  Google Scholar 

Ter VE, Mohammad NH, Lodder P, Ngai LL, Samaan M, van Oijen MG, et al. The efficacy and safety of S-1-based regimens in the first-line treatment of advanced gastric cancer: a systematic review and meta-analysis. Gastric Cancer. 2016;19:696–712.

Article  Google Scholar 

Furuse J, Okusaka T, Boku N, Ohkawa S, Sawaki A, Masumoto T, et al. S-1 monotherapy as first-line treatment in patients with advanced biliary tract cancer: a multicenter phase II study. Cancer Chemother Pharmacol. 2008;62:849–55.

Article  CAS  PubMed  Google Scholar 

Nishiyama O, Taniguchi H, Kondoh Y, Takada K, Baba K, Saito H, et al. Phase II study of S-1 monotherapy as a first-line treatment for elderly patients with advanced nonsmall-cell lung cancer: the Central Japan Lung Study Group trial 0404. Anticancer Drugs. 2011;22:811–6.

Article  CAS  PubMed  Google Scholar 

Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388:248–57.

Article  CAS  PubMed  Google Scholar 

Miao Y, Zhan P, Lv T, Song Y. A meta-analysis of safety and efficacy on first-line S-1 therapy in cancer patients. Transl Lung Cancer Res. 2015;4:487–97.

CAS  PubMed  PubMed Central  Google Scholar 

Esmaeli B, Golio D, Lubecki L, Ajani J. Canalicular and nasolacrimal duct blockage: an ocular side effect associated with the antineoplastic drug S-1. Am J Ophthalmol. 2005;140:325–7.

Article  CAS  PubMed  Google Scholar 

Chikama T, Takahashi N, Wakuta M, Nishida T. Noninvasive direct detection of ocular mucositis by in vivo confocal microscopy in patients treated with S-1. Mol Vis. 2009;15:2896–904.

CAS  PubMed  PubMed Central  Google Scholar 

Kobashi H, Kamiya K, Simizu K. A case of corneal epithelial lesion and keratoconjunctival pigmentation due to anticancer drug S-1. Jpn J Ophthalmol. 2011;55:165–73.

Article  Google Scholar 

Kim KH, Kim SW. Corneal limbal stem cell deficiency associated with the anticancer drug S-1. Optom Vis Sci. 2015;92:S10–3.

Article  PubMed  PubMed Central  Google Scholar 

Kim N, Park C, Park DJ, Kim H-H, Kim S, Kim YJ, et al. Lacrimal drainage obstruction in gastric cancer patients receiving S-1 chemotherapy. Ann Oncol. 2012;23:2065–71.

Article  CAS  PubMed  Google Scholar 

Sasaki T, Miyashita H, Miyanaga T, Yamamoto K, Sugiyama K. Dacryoendoscopic observation and incidence of canalicular obstruction/stenosis associated with S-1, an oral anticancer drug. Jpn J Ophthalmol. 2012;56:214–8.

Article  CAS  PubMed  Google Scholar 

Yamada R, Sotozono C, Nakamura T, Nishida A, Nakanishi S, Hirabatake M, et al. Predictive factors for ocular complications caused by anticancer drug S-1. Jpn J Ophthalmol. 2016;60:63–71.

Article  CAS  PubMed  Google Scholar 

Tabuse H, Kashiwagi H, Hamauchi S, Tsushima T, Todaka A, Yokota T, et al. Excessive watering eyes in gastric cancer patients receiving S-1 chemotherapy. Gastric Cancer. 2016;19:894–901.

Article  CAS  PubMed  Google Scholar 

Moriya K, Shimizu H, Handa S, Sasaki T, Sasaki Y, Takahashi H, et al. Incidence of ophthalmic disorders in patients treated with the antineoplastic agent S-1. Jpn J Cancer Chemother. 2017;44:501–6.

CAS  Google Scholar 

Kim N, Kim JW, Baek J-H, Kim J-S, Choung H-K, Kim T-Y, et al. S-1-induced lacrimal drainage obstruction and its association with ingredients/metabolites of S-1 in tears and plasma: A prospective multi-institutional study. Cancer Res Treat. 2018;50:30–9.

Article  CAS  PubMed  Google Scholar 

Lemp MA. Report of the National Eye Institute/Industry workshop on clinical trials in dry eyes. CLAO J. 1995;21:221–32.

CAS  PubMed  Google Scholar 

van Bijsterveld OP. Diagnostic tests in the Sicca syndrome. Arch Ophthalmol. 1969;82:10–4.

Article  PubMed  Google Scholar 

Dogru M, Katakami C, Inoue M. Tear function and ocular surface changes in noninsulin-dependent diabetes mellitus. Ophthalmology. 2001;108:586–92.

Article  CAS  PubMed  Google Scholar 

Nakamura J, Kamao T, Mitani A, Mizuki N, Shiraishi A. Accuracy of the lacrimal syringing test in relation to dacryocystography and dacryoendoscopy. Clin Ophthalmol. 2023;17:1277–85.

Article  PubMed  PubMed Central  Google Scholar 

Akune Y, Yamada M, Shigeyasu C. Determination of 5-fluorouracil and tegafur in tear fluid of patients treated with oral fluoropyrimidine anticancer agent, S-1. Jpn J Ophthalmol. 2018;62:432–7.

Article  CAS  PubMed  Google Scholar 

Fujita K, Yamamoto W, Endo S, Endo H, Nagashima F, Ichikawa W, et al. CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1. Cancer Sci. 2008;99:1049–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Peters GJ, Noordhuis P, Van Kuilenburg ABP, Schornagel JH, Gall H, Turner SL, et al. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydr oxypyridine (molar ratio 1:0.4:1) in patients with solid tumors. Cancer Chemother Pharmacol. 2003;52:1–12.

Article  CAS  PubMed  Google Scholar 

Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. Prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma. A Mid-Atlantic Oncology Program Study. J Clin Oncol. 1989;17:425–32.

Article  Google Scholar 

Yasui H, Kawakami T, Kashiwagi H, Mori K, Omae K, Kasai J, et al. Pharmacokinetics of S-1 monotherapy in plasma and in tears for gastric cancer patients. Int J Clin Oncol. 2019;24:660–5.

Article  CAS  PubMed  PubMed Central  Google Scholar